Theranexus SA (ALTHX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Theranexus SA (ALTHX) has a cash flow conversion efficiency ratio of -0.305x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-883.76K ≈ $-1.03 Million USD) by net assets (€2.90 Million ≈ $3.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Theranexus SA market cap and net worth for the company's overall valuation and market capitalisation.
Theranexus SA - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Theranexus SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Theranexus SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Theranexus SA ranked by their cash flow conversion efficiency. Explore ALTHX operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sangsangin Industry Co. Ltd.
KQ:101000
|
-0.035x |
|
FORTE MINERALS CORP.
F:2OA
|
-0.055x |
|
Ma Kuang Healthcare Holding Ltd
TWO:4139
|
0.097x |
|
Nordwest Handel AG
F:NWX
|
N/A |
|
Sam-A Pharm. Co. Ltd
KQ:009300
|
0.001x |
|
MacroWell OMG Digital Entertainment Co Ltd
TWO:3687
|
0.021x |
|
Shinih Enterprise Co Ltd
TW:9944
|
0.006x |
|
Freightos Limited Ordinary shares
NASDAQ:CRGO
|
-0.036x |
Annual Cash Flow Conversion Efficiency for Theranexus SA (2015–2025)
The table below shows the annual cash flow conversion efficiency of Theranexus SA from 2015 to 2025. View today's stock price for Theranexus SA for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €2.90 Million ≈ $3.39 Million |
€-883.76K ≈ $-1.03 Million |
-0.305x | -114.98% |
| 2024-12-31 | €-1.66 Million ≈ $-1.94 Million |
€-3.37 Million ≈ $-3.94 Million |
2.033x | +171.04% |
| 2023-12-31 | €2.22 Million ≈ $2.60 Million |
€-6.36 Million ≈ $-7.43 Million |
-2.862x | -205.08% |
| 2022-12-31 | €5.73 Million ≈ $6.70 Million |
€-5.37 Million ≈ $-6.28 Million |
-0.938x | -52.84% |
| 2021-12-31 | €10.18 Million ≈ $11.90 Million |
€-6.25 Million ≈ $-7.31 Million |
-0.614x | -11.20% |
| 2020-12-31 | €10.28 Million ≈ $12.02 Million |
€-5.68 Million ≈ $-6.64 Million |
-0.552x | -8.61% |
| 2019-12-31 | €9.98 Million ≈ $11.66 Million |
€-5.07 Million ≈ $-5.93 Million |
-0.508x | -21.77% |
| 2018-12-31 | €13.41 Million ≈ $15.68 Million |
€-5.60 Million ≈ $-6.54 Million |
-0.417x | -312.77% |
| 2017-12-31 | €18.71 Million ≈ $21.87 Million |
€-1.89 Million ≈ $-2.21 Million |
-0.101x | +99.38% |
| 2016-12-31 | €89.85K ≈ $105.05K |
€-1.47 Million ≈ $-1.72 Million |
-16.406x | -3069.12% |
| 2015-12-31 | €1.68 Million ≈ $1.96 Million |
€-867.96K ≈ $-1.01 Million |
-0.518x | -- |
About Theranexus SA
THX Pharma Société Anonyme, a biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders. It is involved in the development of Batten-1, an initial drug candidate currently under Phase ½ clinical study for Batten disease. The company was formerly known as Theranexus Société Anonyme and change its name to THX Pharma Société Anonym… Read more